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Background: Anti-malarial drugs inhibit coronaviruses in-vitro. Few published studies
have evaluated the safety and efficacy of these drugs in the treatment of
COVID-19 infection.
Materials and Methods: This is a systematic review and meta-analysis of clinical trials
and observational studies. Major database searches were carried out up until June 5,
2020. Participants admitted with RT-PCR-confirmed SARS Cov-2 (COVID-19) infection
were included. The “Intervention group” received anti-malarial drugs with or without other
drugs (Azithromycin) administered as an adjunct to the standard treatment/care. The
“Control group” received treatment except anti-malarial drugs. The primary outcome
is “all-cause mortality.” Secondary outcome measures were effects on clinical and
laboratory parameters and adverse events.
Results: Of 3,472 citations, 17 (six clinical trials and 11 observational studies) studies
provided data of 8,071 participants. Compared to the control, Hydroxy-chloroquine
(HCQ) has no significant effect on mortality [(OR 0.87; 95% CI 0.46–1.64); eight
observational studies;N= 5,944]. Data from a single, small non-randomized trial (N= 42)
also reached a similar conclusion (OR 1.94; 95% CI 0.07–50.57; p = 0.69). Compared
to the control, HCQ plus Azithromycin (AZM) significantly increased mortality [(OR 2.84;
95% CI 2.19–3.69); four observational studies; N = 2,310]. Compared to the control,
risk of any adverse event was significantly increased in HCQ group [(OR 3.35; 95% CI
1.58–7.13); four clinical trials; N = 263]. Compared to control, risk of adverse cardiac
events (abnormal ECG, arrhythmia, or QT prolongation) were not significantly increased
in HCQ group (but significantly increased in the HCQ plus AZM group). The GRADE
evidence generated for all the outcomes was of “very low-quality.”
Conclusions: As very low quality evidence suggests an increased risk of mortality and
adverse event with HCQ plus Azithromycin combination (not HCQ alone), caution should
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be exercised while prescribing this combination for treatment of hospitalized adults with
COVID-19 infection. Good quality, multi-centric RCTs (including both hospitalized and
non-hospitalized patients) are required for any firm recommendation to be made during
the ongoing pandemic.
OSF Protocol Registration Link: https://osf.io/6zxsu.
Keywords: aminoquinoline, azithromycin, SARS-CoV-2, evidence-based medicine, COVID-19, mortality,
Chloroquine, Hydroxychloroquine
INTRODUCTION
COVID-19, also known as severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, in
late 2019. It is a highly contagious disease with a global
average mortality rate of 4.6% (1). There have been ongoing
efforts to develop effective treatment modalities for this dreaded
pandemic. Currently, no specific therapies against SARS-CoV-2
infection exist, and a series of therapeutic agents (e.g., antiviral
agents, antibiotics, immune-modulators, inhaled nitric oxide,
and convalescent plasma) have been repurposed with negative to
inconclusive evidence available (2). There has been an increased
interest in two existing anti-malarial drugs belonging to amino-
quinoline group (Chloroquine and Hydroxy-chloroquine) to
treat COVID-19. This is because of the inhibitory effects of
these two drugs on other coronaviruses, such as SARS-CoV-1
(2, 3). The plausible mechanism of actions includes inhibition
of angiotensin converting enzyme 2 (ACE-2) present on the
cell surface for virus entry (by reduction of glycosylation in the
enzyme) (4, 5), inhibition of release of viral particles into intra-
cellular space (6, 7), and an anti-inflammatory effect (inhibition
of interleukin-6, the tumor necrosis factor, the aberrant
interferon, and other pro-inflammatory cytokines that cause lung
injury leading to acute respiratory distress syndrome) (6, 8).
Chloroquine and Hydroxy-chloroquine (HCQ) are both cost-
effective and considered safe as per their approved indications.
Compared to Chloroquine (CQ), Hydroxy-chloroquine (HCQ) is
more soluble and less toxic and is considered safer (9, 10). It has
to be kept in mind that these drugs are not entirely safe because
of the risk of some serious side-effects (e.g., neuro-psychiatric,
retinal, cardiac, and hypoglycemia), and there have been reports
of toxicities in people who are self-medicating (11, 12).
There have been published studies evaluating the safety
and/or efficacy of these agents (alone or in combination)
compared to a control arm or parallel intervention, to treat
patients with COVID-19 (13–32). However, the results have
been contradictory. Earlier published rapid systematic reviews
have concluded the role of anti-malarial drugs in patients with
COVID-19 is still uncertain, and its routine use should not be
recommended until more evidence is available from ongoing
studies (33, 34). However, these systematic reviews neither
included larger observational studies and randomized clinical
trials (RCTs) published recently nor provided quality (GRADE)
of evidence in a more systematic manner. In addition, findings
from an ORCHID (Outcomes Related to COVID-19 treated
with hydrox-ychloroquine among In-patients with symptomatic
Disease) study have shown that HCQ neither harms nor benefits
patients with COVID-19 infection (35). The present systematic
review is an endeavor in this direction to synthesize the available
evidences to inform clinical practice and guide the international
agencies to formulate recommendations.
MATERIALS AND METHODS
This systematic review protocol is registered at the Open Science
Forum (OSF) registration link: https://osf.io/6zxsu.
Types of Studies
Both clinical trials (randomized, quasi- randomized, and non-
randomized) and observational studies comparing anti-malarial
drugs (Chloroquine and Hydroxy-chloroquine) alone or in
combination with other drugs vs. a control (standard of care)
or other treatment were included. As a majority of the studies
were published on pre-print servers (for rapid dissemination of
knowledge) prior to publication in peer-reviewed journals, we
planned to include these studies in the present meta-analysis after
taking permission from the study authors.
Types of Participants
Children of 12–18 years of age and adults with RT-PCR-
confirmed SARS Cov-2 (COVID-19) cases treated in the hospital
were included. Exclusion criteria were an allergy to anti-malarial
drugs [Chloroquine (CQ) and Hydroxy-chloroquine (HCQ)],
retinopathy, hearing loss, and severe neuro-psychiatric diseases.
Types of Interventions
(a) Interventions included anti-malarial drugs (CQ and HCQ)
provided in various formulations and dose schedules. Based
on a previous study, the following dose schedules were
considered: HCQ—a loading dose of 400mg twice daily
(BID) followed by a maintenance dose of 200mg BID
for 4 days; and CQ-−500mg BID for 5 days (9). The
intervention was administered as an adjunct to other
treatment modalities [including Azithormycin (AZM)] to
patients infected with SARS Cov-2 (COVID-19). Those in
the control group received supportive treatments without
CQ/HCQ. We also included trials comparing different doses
(high dose vs. low-dose of anti-malarial drugs) to provide
more information and urgent dissemination of knowledge
during the current pandemic.
(b) Supportive and additional treatment included various
methods. In hospitalized cases, it varied from bed rest,
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nebulization, and oxygen inhalation to invasive respiratory
support (mechanical ventilation) and maintenance of
vital parameters. In addition, additional treatment during
the current pandemic included antibiotics, non-specific
anti-viral drugs [Remdesivir, Lopinavir/Ritonavir, IFN-
α/β, Umifenovir [Arbidol], Entecavir, Ribavirin, and/or
Oseltamivir], Immuno-modulators (Immunoglobulin,
Tocilizumab, and Sarilumab), steroids, and NSAIDs
(including Aspirin). There is evidence that non-specific
antiviral drugs may not benefit patients with Covid-19,
though Remdesivir and immune modulators may have some
role in severe or critical cases (36, 37).
Types of Outcome Measures
Primary
1. All-cause mortality: patients with Covid-19 dying from
any cause.
Secondary
1. Time to clinical recovery: time taken for normalization of
temperature, respiratory distress, and relief of cough or no
cough for 72 h
2. Proportion of patients with clinical recovery: proportions
of patients with normalization of temperature, respiratory
distress, and relief of cough or no cough for 72 h
3. Proportion of patients requiring escalation of respiratory
support (including mechanical ventilation) or requiring
ICU transfer: escalation of respiratory support defined
as progressive change in the requirement of respiratory
support to maintain normal oxygen saturation (SpO2) and
vital parameters
4. Proportion of patients developing severe disease:
proportions of patients developing severe disease as
defined as per the National Institute of Health (NIH)
COVID-19 Treatment Guidelines (37)
5. Duration of hospitalization: the time from admission (days)
to either discharge or death
6. Duration of ICU stay: the time from admission (days) to ICU
to death or transfer back to non-critical areas
7. Time to negative PCR results for COVID-19: the time taken
for two consecutive negative reports of a positive patient
8. Proportion of patients with negative PCR results for
COVID-19 after day 3, 5, 7, 10, 14, 21, and 28: proportions
of patients with two consecutive negative reports after a
positive report
9. Proportion of patients with improved radiological features
after day 3, 5, 7, 10, 14, 21, and 28: proportions of patients
with improvement noted in either chest X ray or CT scan of
chest compared to that done at baseline
10. Effect on hematological parameters (including inflammatory
markers): these include the blood parameters (complete
blood count, differential counts, and platelet count),
acute phase reactants (ESR, CRP, and pro-calcitonin), and
inflammatory markers (IL-6, TNF-α, etc.)
11. Adverse events: developing secondary to the use of anti-
malarial drugs alone or in combination with other drugs.
Search Methodology
The following major databases were searched systematically from
1970 till June 5, 2020: Cochrane Central Register of Controlled
Trials (CENTRAL), PubMed/MEDLINE, Google Scholar, and
EMBASE (Appendix 1). We also searched the Pre-print servers
(medRxiv, bioRxiv, OSF pre-prints, Pre-prints.org) till June 5,
2020. The PubMed/Medline search strategy used the various
MeSH and free text terms for “novel corona virus,” “COVID
19,” “Hydroxychloroquine,” and “Chloroquine” combined using
the Boolean operators. No language restrictions were applied.
Three reviewers (RRD, NJ, and ND) reviewed the search results
to identify relevant studies.
Data Extraction
Data extraction was done using a data extraction form that was
designed and pilot tested a priori. Three authors (NJ, ND, and
SSN) independently extracted the following information from
each study: author; year; location (country); study design (clinical
trial or observational study); setting (hospital or community);
method of recruitment; inclusion criteria; unit of analysis;
allocation ratio In case of RCT); risk of bias; participants (age, sex,
sample size, and disease severity); intervention (dosage, duration,
frequency, and co-intervention if any); outcomes (outcome
definition, valid unit of measurement, time points of collection
and reporting); loss to follow-up; and miscellaneous (key
conclusions, references to other relevant trials, and additional
data required).
Assessment of Risk of Bias in the Included
Studies
Two review authors independently (NJ and SSN) assessed
the methodological quality of the selected trials by using
methodological quality assessment forms and the criteria
outlined in the Cochrane Handbook for Systematic Reviews of
Interventions (38). Quality assessment was undertaken using the
Newcastle Ottawa Scale (NOS) for observational studies. This
scale assesses the quality under three major headings, namely,
selection of the studies (representativeness and the exposure
assessment/control selection), comparability (adjustment for
main/additional confounders), and outcome/exposure (adequacy
of outcome measured, exposure measured vs. self-report) (39).
Quality assessment was undertaken using the ROBINS-I tool for
non-randomized trials (40). Any disagreements between the two
review authors were resolved through discussion with a third
author (JS).
Dealing With Missing Data
We described missing data, including dropouts in included
studies. Differential dropout rates can lead to biased estimates of
the effect size, and bias may arise if the reasons for dropping out
differ across groups. We reported reasons participants dropped
out of studies as mentioned by the authors. If data were missing,
or if reasons for dropping out were not reported, we contacted
the authors for further information.
Data Synthesis
Data were analyzed using Review Manager (RevMan) V.5.1
(The Nordic Cochrane Center, The Cochrane Collaboration,
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Copenhagen, Denmark) (41). The data from various studies
were pooled and expressed as mean difference (MD) with 95%
confidence interval (CI) in case of continuous data, and odds
ratio (OR) with 95% CI in case of categorical data. Where data
were expressed as a median (IQR), we calculated the mean and
SD by the statistical formula described previously (42). The
primary pooled analysis of all the reports was conducted using the
Generic Inverse Variancemethod using random effects weighting
(43), where the log RRs for cohort studies or log ORs for case–
control studies were weighted by the inverse of the variance to
obtain a pooled RR estimate. Since nested case-cohort and nested
case–control studies are temporally prospective, we analyzed data
from these studies with the prospective studies. A p < 0.05 was
considered statistically significant. Inter-study heterogeneity was
assessed by Cochrane’s Q (χ2 p< 0.10) and quantified by I2. An I²
≥ 50% indicated “substantial” heterogeneity and≥75% indicated
“considerable” heterogeneity (44). The cause of substantial and
considerable heterogeneity was explored, and sensitivity and/or
sub-group analyses were carried out.
Publication Bias
To evaluate for any possible publication bias, we constructed the
funnel plot from primary outcome data (45).
Grade of Evidence
To assess the quality of evidence we used GRADE Profiler
software (V.3.2) (46, 47). The software uses five parameters
for rating the quality of evidence. The parameters used
were limitations to design of randomized controlled trials,
inconsistency of results or unexplained heterogeneity,
indirectness of evidence, imprecision of results, and publication




Of 3,472 total citations retrieved, the full texts of 49 papers
were assessed for eligibility, and 29 were excluded for various
reasons (Figure 1). Of the remaining 20 eligible studies, 14 were
published in peer-reviewed journals (13–29) and six in pre-
print servers (not peer-reviewed) (17, 28–32). We contacted
the authors of these six studies to give us their permission
to use their data in the meta-analysis, but only three authors
gave their permission (17, 28, 29). We therefore included the
data of three studies in the meta-analysis and described the
characteristics of the remaining three studies using a separate
table (Supplementary Table 1). Finally, we were able to conduct
a meta-analysis of a total of 17 studies (six clinical trials and 11
observational studies) including 8,071 patients (Adults = 8,041;
Adolescents = 30) (Table 1). Twenty-nine studies were excluded
for the following reasons: 19 were case series (without having a
control/comparator that is inclusion criteria of present review),
nine studies mentioned about intervention but did not provide
outcome data for them separately, and one study reported use
of anti-malarial drugs with or without AZM in rheumatoid
arthritis (RA) patients for non-RA indications (including viral
and other infections).
Of 17 published peer-reviewed studies included, six clinical
trials provide data of 381 patients, and the 11 observational
studies provided data of 8,071 patients. A total of 4,009 patients
received HCQ or CQ (clinical trials = 226, observational studies
= 3,783), and 1,255 received a combination of HCQ plus
Azithromycin (clinical trials= 06, observational studies= 1,249).
The studies were conducted in following countries: USA (five
studies, 3,985 patients), Spain (two studies, 2,185 patients), China
(four studies, 752 patients), France (two studies, 217 patients),
Brazil (one study, 81 patients), and the UAE (one study, 34
patients). One trial compared high vs. low-dose of Chloroquine
(18). One clinical trial (13) and six observational studies (19–22,
25, 27); each had three arms of comparison (HCQ, HCQ+AZM,
and Control). Two studies included data on adolescents (<18
years) (13, 21). Two studies used Azithromycin but did not
provide separate outcome data for both the groups (19, 20). Of
the six clinical trials, three were described as double blinded, two
were open label, and one was a non-randomized trial.
As shown in Table 1, the age of included participants,
severity of illness, dose schedule, and timing of administration
of intervention (HCQ/CQ) varied widely among the studies.
Majority of the participants in the clinical trials were ≤50 yr of
age, whereas, majority of the participants in the observational
studies (except one) were ≥60 yr of age. Around 72% of
participants in the clinical trials were having mild and moderate
illness, whereas <40% of the participants in the observational
studies were having mild and moderate illness. One study
included only cancer patients (27). The dose of CQ was nearly
uniform (except one RCT comparing high and low-dose) with
duration varying from 5 to 10 days. The dose of HCQ varied
widely with the lowest dose being 200 mg/d−1,200mg on day
1 followed by variable doses for variable period (sometime till
discharge/death). Two studies did not provide any information
on dose schedule of HCQ (26, 27). The median time from onset
of symptom to admission or treatment initiation was ≤8 days in
all but two studies (one RCT has 17 days, and one observational
study has 10 days). Two studies did not provide any information
on the timing of initiation of HCQ (26, 27). Except one study
(17), no other study was able to start the intervention (HCQ/CQ)
in the early phase of illness (within 48 h of symptom onset), which
is regarded as the golden window for antiviral treatment (e.g., in
influenza) (48).
Risk of Bias in Included Studies
The details have been provided in Appendix 2. Except two trials
(17, 18), others had low to high-risk of bias in different domains.
One non-randomized trial had a serious risk of bias overall (13).
Of the 11 observational studies, five were at a high risk of bias for
selection of cases (22, 23, 25, 28, 29). Except for one study (27),
the remaining 10 studies were at a high risk of bias for selection
of controls and a low risk of bias for the exposure parameters.
Effect of Interventions
Primary Outcomes (All-Cause Mortality)
HCQ vs. control
(i) overall results: Three trials reported no mortality in any of
the groups. One Non-RCT (N = 42) found no significant
difference in the mortality rate between HCQ and control
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FIGURE 1 | PRISMA flow diagram.
group (OR 1.94; 95% CI 0.07–50.57; p = 0.69) (13)
(Supplementary Figure 1). Eight observational studies (N
= 5,944) reported mortality rate, and found no significant
difference between the HCQ and control group (OR 0.87;
95% CI 0.46–1.64; p= 0.66; I2 = 92%) (Figure 2) (19–21, 23,
25–27, 29).
(ii) Subgroup analysis (data from observational studies):
Mortality rate was found to be significantly increased in the
HCQ group in the studies from USA (OR 1.71; 95% CI 1.38–
2.13; p < 0.001; I2 = 0%; N = 3,036) (20, 21, 25, 27), whereas
a significantly decreased mortality rate was found in the
studies conducted outside USA (N = 2,908) population (OR
0.38; 95% CI 0.23–0.63; p < 0.001; I 2 = 56%) (19, 23, 26, 29).
The heterogeneity was not significant once we separated
studies conducted in USA vs. outside USA. Two studies
(20, 23) compared mortality rate in participants aged ≤60
vs. >60 yr and found significantly increased risk in those
>60 yr age [data provided as hazard ratio [not raw data]].
One study used HCQ after 48 h of admission and two studies
had no information on timing; when these two studies were
omitted, no difference in mortality was found (OR 1.24; 95%
CI 0.7–2.18; p = 0.46; I2 = 82%) (23, 26, 27). When studies


























































N: 36 (HCQ = 14;




Age (yr): >12 yr (HCQ =








(200mg TID) for 10
days.
HCQ+AZM: AZM
500mg on day 1
followed by 250mg OD
for 4 days in addition to
HCQ.
Mean (SD): 4.1 (2.6) in
HCQ group, and 3.9
(2.8) in Control group.
Symptomatic and antibiotics. HCQ group recruited in one center and
control group in another. Control group
included those refused intervention or
were not eligible for it. Attrition rate 23%









Age (yr): >18 yr (HCQ =
50.5 ± 3.8; Control =
46.7 ± 3.6).
Male: 70%.
Severe illness or other
measures of severity not
defined.
HCQ: 400 mg/d (OD) for
5 days.




group (80%), Control group
(67%).
Lopinavir/Ritonavir: HCQ
group (0%), Control group
(13%).
Underlying co-morbidities: hypertension
(27%), diabetes (7%), and chronic
obstructive lung disease (3.5%). Started






N: 150 (HCQ = 75;
Control = 75).
Additional inclusion
criteria: A Chest CT
scan needed before
randomization.
Age (yr): >18 yr (HCQ =






HCQ: 1,200 mg/d for 3
days followed by 800
mg/d for the remaining
days (total treatment
duration: 2 weeks for
mild/moderate and 3
weeks for severe cases).
Mean: 16.6 (HCQ







Trial stopped early (intended to enroll
360 patients-−180 in each arm).
Underlying co-morbidities (30%):
diabetes (14%), hypertension (6%), and
others (20.7%). Funded study.








Age (yr): >18 yr (CQ
[median, IQR] = 41.5
[33.8–50]; Control










(100mg): BID for 10
days in the control
group.
Median: 2.5 in CQ






(18.2%), diabetes (9.1%), smoking
(9.1%), and cerebro-vascular disease





N: 62 (CQ = 31; Control
= 31).
Additional inclusion
criteria: Chest CT with
pneumonia; SaO2/SPO2
ratio > 93% or
PaO2/FIO2 ratio > 300
mmHg (mild illness).
Age (yr): >18 yr (HCQ =
44.1 ± 16.1; Control =
45.2 ± 14.7).
Male: 46.8%.
Mild: 100% HCQ: 400 mg/d
(200mg BID) for 5 days.
Both groups had fever






and Immunoglobulin, with or
without Corticosteroids.
No information on underlying
co-morbidities. Significant deviation
from registered protocol. Funded study.





































































































N: 81 (CQ high-dose =
41; CQ low-dose = 40).
Additional inclusion
criteria: RR >24/min
and/or HR >125 bpm
and/or SpO2 <90% in
ambient air and/or
shock.
Age (yr): >18 yr (CQ
high-dose = 54.7 ±
13.7; CQ low-dose =
47.4 ± 13.3).
Male: 75.3%.
Severe: 89% (33% were
critical)
High-dose CQ: 600mg
BID for 10 days (total
dose 12 g).
Low-dose CQ: 450mg
BID on day 1 followed
by OD for 4 days (total
dose 2.7 g).
Ceftriaxone (7 days) plus
azithromycin (5 days) in all
cases, and Oseltamivir (5
days) in 87% cases.
Co-morbidities: hypertension (45.5%),
alcohol disorder (27.5%), and diabetes
(25.5%). Older and more heart disease
(high-dose = 17.9%, low-dose = 0) in









by mask or nasal prongs
(WHO progression
scores of 5).
Age (yr): >18 yr (HCQ
[median, IQR] = 59
[48–67]; Control
[median, IQR] = 62
[55–69].
Male: 72%.
Severe: 100%. HCQ: 600 mg/d Median: 7 (HCQ started
within 24 h of admission
except in 8 cases).
Respiratory support,
Azithromycin (HCQ = 18%,
Control = 29%); Amoxicillin
and Clavulanic acid (HCQ =
52%, Control = 28%).






respiratory disease (11%), diabetes
(9%), and chronic kidney disease (5%).









Age (yr): >18 yr [Majority
were ≥60 years of age
(60.5%)].
Male: 56.8%.
Severe illness or other
measures of severity not
defined (HCQ group
were more severely ill
than control group).
HCQ: 600mg BID on
day 1 followed by
400mg OD for 4 days.
Not mentioned (in 86%
cases, HCQ started










hypertension (31.7%), chronic lung
disease (18.2%), chronic kidney








N: 1,438 (HCQ = 271;
HCQ+AZM = 735; AZM












group: 10% critically ill).
Only HCQ group had the













OD or BID schedule
(variably used).
Median: three in the
HCQ group, two in the
HCQ+AZM group, and
four in the Control group
(HCQ started within 48 h
of admission).
Respiratory support, Aspirin
(19.8%), and NSAIDs (3.6%).
Included 25 children. Co-morbidities:
diabetes (35%), obesity (30.4%),
cardio-vascular disease (30.4%),
chronic lung disease (18%), smoking
(17.4%), kidney disease (13%),
dementia (6.5%), and cancer (3.8%).
Patients entered the ICU/mechanical
ventilated, often with HCQ and AZM
initiation, rendered these outcomes
unsuitable for efficacy analyses.
Adverse events were collected,
potentially before drug initiation. Conflict
of interest unclear (spouse of one









































































































Age (yr): >18 yr (mean
± SD = 58.5±9.1).
Male: 57.2%.
Severe illness or other
measures of severity not
defined.
CQ/HCQ: CQ 500mg
BID on day 1 followed
by OD for 4 days; HCQ
400mg BID on day 1
followed by 200mg BID
for 4 days (total 5 days.
HCQ+AZM: AZM
500mg OD for 5 days in
addition to above.
Not mentioned. Respiratory support. Co-morbidities: hypertension (60.2%),
hyperlipidemia (41.8%), diabetes
(32.3%), chronic lung diseases (14.9%),
coronary artery disease (11.4%), heart
failure (7.5%), atrial fibrillation (7%), and
chronic kidney disease (5%). No
virological outcome studied.
Non-funded study.
Yu et al. China
(Single- center)
(23)





ill (corresponding to a
WHO progression score
of 5).
Age (yr) [median (IQR)]:
>18 yr [HCQ = 68
(60–75); Control = 68
(59–77)].
Male: 62.5%.
Critically ill (100%). HCQ: 400 mg/d
(200mg BID for 7–10
days).




hydrate, or Ribavirin), IVIg,
antibiotics, and Interferon (no
Interferon in HCQ group).
Co-morbidities were: hypertension
(45.8%), diabetes (17.1%), coronary









Age (yr) [median (IQR)]:
>18 yr [CQ = 43







(OD or BID) for 10 days.

























data on body mass
index, vital parameters.
Age (yr) [median (IQR)]:
>18 yr [HCQ = 71
(62–76.8); HCQ+AZM
= 68 (59–74); Control =
70 (59–77)].
Male: 95.7%
All severity included (no
severity subgroups
mentioned).
HCQ [median (IQR) daily
dose]: 400 (400–480)
mg in HCQ group, and
422.2 (400–480) mg in
HC+AZM group for
median (IQR duration of
5 (3–6) d.
Not mentioned (HCQ
and AZM started within
24 h).
Respiratory support, and




(42.9%), renal disease (25%), chronic
pulmonary disease (19.6%), malignancy
(18%), hyper-lipidemia (15.8%),
cerebro-vascular diseases (15%),
smoking (14.1%), liver disease (9.2%),
dementia (8.4%), asthma (6%), and
HIV/AIDS (2.4%). There were significant
differences among the three groups in
baseline demographic characteristics,
selected vital signs, laboratory tests,





































































































Number: 2,019 (HCQ =
1,857; Control = 162).
Additional inclusion
criteria: None.
Age (yr): >18 yr (HCQ =
67.11 ± 15.51; Control
= 73.47 ± 16.22)
Male: 57.3%.

















Number: 756 (HCQ =





Age (yr) [median (IQR)]:
>18 yr [66 (57–76)].
Male: 50%.










and obesity (19%). Funded study.









Age (yr): [median (IQR)]:
>18 yr [HCQ = 33 (31 –






(400mg BID) on day 1
400 mg/d for 10 days.





asthma (8.8%), diabetes (5.9%), heart
disease (2.9%), renal disease (2.9%),
and immunosuppressant use (2.9%).
Co-morbidities and D-dimer levels were





Number: 166 (HCQ =






Age (yr): >18 yr (HCQ =







+ 400mg) loading dose
on day 1 followed by
400mg OD.
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dyslipidemia (34.3%), heart disease
(22.3%), diabetes (17.5%), cancer
(13.9%), and pulmonary disease
(14.4%).
HCQ, Hydroxychloroquine; CQ, Chloroquine; AZM, Azithromycin; RT-PCR, Reverse transcription polymerase chain reaction; MV, Mechanical ventilation; COPD, Chronic obstructive pulmonary disease; URTI, Upper respiratory tract
infection; LRTI, Lower respiratory tract infection; ARDS, Acute respiratory distress syndrome; IQR, Inter-quartile range; ICU, Intensive care unit; WHO, World health organization; OD, Once daily; BID, Twice daily; NSAIDs, Non-steroidal
anti-inflammatory drugs; IVIg, intravenous immunoglobulin.
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FIGURE 2 | All-cause mortality (HCQ vs. control; observational studies).
FIGURE 3 | All-cause mortality (HCQ + AZM vs. control; observational studies).
with median time from onset of symptom to admission
or treatment initiation of >8 days were excluded, and no
significant difference was found (OR 1.24; 95% CI 0.7–2.18;
p = 0.46; I2 = 82%). We could not carry out subgroup
analyses of mortality rate in participants with and without
co-morbidity, as these data were not provided separately by
the included studies. When studies that did not follow the
recommended dose schedule of HCQ/CQ were excluded,
still no significant difference was found (OR 0.83; 95% CI
0.36–1.88; p= 0.65; I2 = 90%).
HCQ plus azithromycin (AZM)
Four studies (N = 2,310) reported a significant increase in the
mortality rate in the HCQ plus AZM group compared to the
control group (OR 2.84; 95% CI 2.19–3.69; p < 0.001) (19, 21, 25,
27) (Figure 3). Another study used Azithromycin in treatment
but did not provide separate data (19).
HCQ vs. HCQ plus AZM
Five studies (N = 1,988) reported mortality rate, and found a
significant decrease in HCQ group (OR 0.7; 95% CI 0.54–0.9; p
= 0.006; I2 = 0%) (19, 21, 22, 25, 27).
High-dose vs. low-dose CQ
One RCT (N = 81) found a significantly higher mortality rate
in the high-dose group (OR 3.63; 95% CI 1.24–10.58; p = 0.02)
(Supplementary Figure 2) (18).
Secondary Outcomes
Details have been provided in Table 2. A majority of the outcome
measures favored the Control group (i.e., the Control was better
than HCQ±AZM), and these were the occurrence of adverse
events [any events (Supplementary Figure 3), or only cardiac
events, or only vomiting], development of severe disease, and
duration of hospitalization. Those favored HCQ group (i.e.,
HCQ±AZM was better than Control) were resolution of cough,
proportion of patients with negative COVID-19 PCR after days
5, 10, and 14, proportion of patients with improved radiological
features after day 5, change in IL-6 level (pg/mL), and change in
total leukocyte count (/cumm). The outcomes that favored HCQ
over HCQ plus AZMwere mortality rate and the development of
severe disease. Contrary to common belief, no difference between
HCQ and HCQ plus AZM was found for any type of adverse
cardiac events.
Publication Bias
The funnel plot was asymmetrical showing publication bias
(Supplementary Figure 4). The reasons for publication bias were
heterogeneity among studies, poor methodological design, and
selective outcome reporting.
Grade of Evidence
The evidence generated was of “very low quality” for all the
outcomes (primary and secondary). A detailed analysis of the
summary of evidence is provided in Table 3.
Frontiers in Medicine | www.frontiersin.org 10 July 2020 | Volume 7 | Article 482
Das et al. Anti-malarial Drugs as a Treatment of COVID-19
TABLE 2 | Secondary outcome measures from the included studies.





CLINICAL TRIALS (RANDOMIZED, AND NON-RANDOMIZED)
Hydroxy-chloroquine (HCQ)/chloroquine (CQ) vs. control
Time to alleviation of clinical symptoms (d)
Fever 2 (14, 17) 92 MD 0.21; 95% CI −2.95 to 3.37 0.9
Cough 1 (17) 62 MD −1.1; 95% CI (−1.86 to −0.34) 0.005*
Clinical recovery 1 (15) 119 Could not be pooled 0.96
Time to negative RT- PCR results (d) 2 (14, 15) 180 MD 1.55; 95% CI −0.7 to 3.79 0.18
Escalation of respiratory support (including MV) 1 (13) 42 OR 4.92; 95% CI 0.24 to 101.66 0.3
Development of severe disease 1 (17) 62 OR 0.1; 95% CI 0.0 to 1.88 0.12
Proportion with clinical recovery after day 28 1 (15) 150 OR 0.75; 95% CI 0.39 to 1.46 0.34
Proportion with negative RT- PCR
After day 3 2 (13, 15) 180 OR 1.02; 95% CI 0.16 to 6.6 0.98
After day 5 1 (13) 30 OR 9.33; 95% CI 1.51 to 57.65 0.02*
After day 7 3 (14–16) 202 OR 0.65; 95% CI 0.36 to 1.17 0.15
After day 10 1 (15) 150 OR 0.73; 95% CI 0.37 to 1.47 0.38
After day 14 3 (14–16) 202 OR 0.98; 95% CI 0.44 to 2.15 0.95
After day 21 1 (15) 150 OR 1.49; 95% CI 0.62 to 3.61 0.37
After day 28 1 (15) 150 Not pooled (event NE in HCQ group)
Proportion with improved radiological features
After day 3 1 (14) 30 OR 0.57; 95% CI 0.13 to 2.5 0.46
After day 5 1 (17) 62 OR 3.43; 95% CI 1.1 to 10.7 0.03*
After day 14 1 (14) 30 All patients (HCQ and control group) improved
Adverse events
Any 4 (14–17) 263 OR 3.35; 95% CI 1.58 to 7.13 0.002*
Serious 1 (15) 150 OR 5.88; 95% CI 0.28 to 124.5 0.26
Vomiting 2 (15, 16) 172 OR 8.67; 95% CI 1.32 to 56.99 0.02*
Abdominal complaints 2 (15, 16) 172 OR 0.77; 95% CI 0.12 to 5.11 0.79
Diarrhea 3 (14–16) 202 OR 2.45; 95% CI 0.25 to 24.18 0.44
Transamnitis 2 (14, 15) 180 OR 1.74; 95% CI 0.2 to 14.78 0.61
Kidney injury 2 (14, 15) 180 OR 1.06; 95% CI 0.1 to 11.3 0.96
Hydroxy-chloroquine (HCQ) and azithromycin (AZM) vs. control
Proportion of patients with negative RT-PCR
After day 3 1 (13) 22 OR 15.0; 95% CI 1.32 to 169.89 0.03*
After day 5 1 (13) 22 OR 0.45; 95% CI 0.02 to 10.67 0.62
High-dose vs. low-dose chloroquine (CQ)
Proportion of patients with negative RT-PCR
After day 3 1 (18) 27 No separate data (six patients negative) NE
Adverse events 1 (18) 81 OR 2.27; 95% CI 1.14 to 4.49 0.02*






Hydroxy-chloroquine (HCQ) or Chloroquine (CQ) vs. control
Escalation of respiratory support (including MV) 5 (19–21, 25, 27) 3,247 OR 2.04; 95% CI 0.99 to 4.18 0.05
Development of severe disease 3 (19, 21, 24) 1,038 OR 1.12; 95% CI 0.51 to 2.46 0.77
Duration of hospitalization (d) 5 (21, 23–25, 29) 1,858 MD 2.17; 95% CI 0.21 to 4.13 0.03*
Time to negative RT- PCR results (d) 2 (24, 28) 407 MD 1.14; 95% CI −11.98 to 14.26 0.86
(Continued)
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TABLE 2 | Continued





Proportion of patients with negative RT- PCR
After day 10 1 (24) 373 OR 7.86; 95% CI 4.4 to 14.04 <0.001*
After day 14 2 (24, 28) 407 OR 6.37; 95% CI 3.01 to 13.48 <0.001*
Proportion with improved radiological features
After day 10 1 (24) 71 OR 1.13; 95% CI 0.38 to 3.3 0.83
After day 14 1 (24) 71 OR 0.88; 95% CI 0.32 to 2.46 0.81
Effect on hematological parameters
Change in IL-6 level (pg/mL) 1 (23) 550 MD −20.64; 95% CI −26.24 to −15.04 <0.001*
Change in CRP level (mg/L) 1 (28) 34 MD −4.95; 95% CI −34.17 to 24.27 0.74
Change in total leukocyte count (/cumm) 1 (28) 34 MD −1247.7; 95% CI −2356.6 to −138.7 0.03*
Change in total lymphocyte count (/cumm) 1 (28) 34 MD −190.75; 95% CI −998.12 to 616.62 0.64
Change in serum ferritin (µg/L) 1 (28) 34 MD −165.97; 95% CI −680.53 to 348.59 0.53
Adverse events
Any 1 (24) 373 OR 0.77; 95% CI 0.49 to 1.2 0.25
Abnormal ECG 2 (19, 21) 665 OR 4.17; 95% CI 0.63 to 27.58 0.14
Arrhythmia 2 (21, 22) 693 OR 1.44; 95% CI 0.87 to 2.39 0.16
QT prolongation 3 (19, 21, 22) 866 OR 1.8; 95% CI 0.79 to 4.11 0.16
Cardiac arrest 1 (21) 492 OR 2.17; 95% CI 1.16 to 4.07 0.02*
Diarrhea 2 (21, 28) 865 OR 0.8; 95% CI 0.34 to 1.85 0.60
Hypoglycemia 1 (21) 492 OR 1.23; 95% CI 0.43 to 3.51 0.70
Hydroxy-chloroquine (HCQ) and azithromycin (AZM) vs. control
Escalation of respiratory support (including MV) 4 (19, 21, 25, 27) 2,294 OR 2.18; 95% CI 0.63 to 7.57 0.22
Development of severe disease 1 (21) 492 OR 3.19; 95% CI 2.07 to 4.91 <0.001*
Duration of hospitalization (d) 2 (21, 25) 1,180 MD 3.6; 95% CI 1.6 to 5.61 <0.001*
Adverse events
Abnormal ECG 1 (21) 492 OR 2.28; 95% CI 1.51 to 3.44 <0.001*
QT prolongation 1 (21) 492 OR 1.98; 95% CI 1.08 to 3.63 0.03*
Arrhythmia 1 (21) 492 OR 2.21; 95% CI 1.38 to 3.52 <0.001*
Cardiac arrest 1 (21) 492 OR 2.52; 95% CI 1.44 to 4.42 0.001*
Diarrhea 1 (21) 492 OR 1.68; 95% CI 0.96 to 2.92 0.07
Hypoglycemia 1 (21) 492 OR 1.26; 95% CI 0.51 to 3.12 0.61
Hydroxy-chloroquine (HCQ) vs. HCQ and azithromycin (AZM)
Escalation of respiratory support (including MV) 4 (19, 21, 25, 27) 1,730 OR 0.66; 95% CI 0.41 to 1.05 0.08
Development of severe disease 1 (21) 1,006 OR 0.53; 95% CI 0.38 to 0.75 <0.001*
Duration of hospitalization (d) 1 (25) 262 MD −1.0; 95% CI −2.46 to 0.46 0.18
Adverse events
Abnormal ECG 1 (21) 1,006 OR 1.01; 95% CI 0.74 to 1.38 0.94
QT prolongation 2 (21, 22) 1,207 OR 1.28; 95% CI 0.88 to 1.87 0.20
Arrhythmia 2 (21, 22) 1,207 OR 0.74; 95% CI 0.52 to 1.06 0.10
Cardiac arrest 1 (21) 1,006 OR 0.86; 95% CI 0.58 to 1.29 0.46
Diarrhea 1 (21) 1,006 OR 0.68; 95% CI 0.41 to 1.1 0.12
Hypoglycemia 1 (21) 1,006 OR 0.98; 95% CI 0.45 to 2.12 0.95
OR, Odds ratio; MD, Mean difference; CI, Confidence interval; NE, Not estimable; PCR, Polymerase chain reaction; MV, Mechanical ventilation; ECG, Electrocardiogram.
*P < 0.05 significant.
DISCUSSION
Summary of Evidence
After an extensive search of the literature, we included 17 studies
with data of 8,071 participants. Compared to control, HCQ
alone (not HCQ+AZM combination) has no significant effect on
mortality or risk of adverse cardiac events. The evidence for all
the outcomes was of “very low quality.”
The high mortality and increased risk of adverse events with
anti-malarial drugs noted by some studies may be overestimated
because of the inclusion of an older population with underlying
co-morbidities (including cardiac conditions) and simultaneous
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TABLE 3 | GRADE evidence (anti-malarial drugs ± azithromycin vs. standard of care for patients with COVID-19 infection).
Outcomes No of Participants
(studies)
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The mean duration of
hospitalization (day) in the
intervention groups was
2.17 higher
(0.21 to 4.13 higher)









145 per 1,000 217 more per 1,000 (from
66 more to 402 more)
Proportions with
negative COVID-19











594 per 1,000 309 more per 1,000 (from
221 more to 358 more)
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI, Confidence interval; OR, Odds ratio; MD, Mean difference.
**Secondary outcomes reporting pooled results from minimum two studies with significant difference between groups are reported here.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is
likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on
our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
acase-control study. b Inhomogeneous population with many being >65 years and male (not matched for age and sex confounders). cPatients in both the groups also received additional
treatment which might influence the outcome, but not clearly defined. dThe 95% CI around the pooled effect is wide and different in the included studies. The 95% CI includes no effect.
eBeing published on pre-print server and not in a peer-reviewed journal. fBoth the groups were not homogenous considering the age and sex of the participants. gOpen label trials.
hDifferent dose schedule of intervention used. iSingle study. jSingle country data. kThough described as double-blinded, blinding of investigators, participants, and outcome accessor
unclear. Allocation concealment also unclear. kOne trial is open label. lSignificant statistical heterogeneity. mTwo trials are open label and one double-blinded (but this trial has unclear
blinding and allocation concealment). nWider 95% CI. oDeveloped country setting data that cannot be apply to developing country setting.
use of other cardiotoxic drugs (e.g., Azithromycin, and
Oseltamivir). The same may be difficult to know during the
current pandemic as there is no definitive treatment, and
healthcare professionals all over the world want to administer
these experimental drugs with the hope of saving some lives.
The use of HCQ+AZM has drawn attention, and there are
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differences in opinion regarding use of this combination.
Compared to control, HCQ+AZM combination was found
to increase the mortality rate significantly, in contrast to
HCQ alone. Compared to HCQ+AZM combination, HCQ
alone was significantly decreasing the mortality rate. These
indirect evidences suggest that HCQ+AZM might increase
the mortality rate, and caution should be exercised while
using this combination in vulnerable population (e.g., those
with advanced age, underlying cardiac conditions, and those
receiving medication with cardiac side-effects, as noted in the
included studies).
It has to be kept in mind that, the anti-viral action of anti-
malarial drugs against COVID-19 is still largely unknown (49,
50). An acute systemic inflammatory reaction/cytokine storm
(besides the viral infection itself) is the hallmark of COVID-
19 infection (51). This reaction, once well-established, can cause
rapid disease progression leading to death (52, 53). However,
except for three studies (15, 23, 28), no studies have reported the
effect of anti-malarial drugs on the inflammatory markers and
blood counts (lymphocyte, neutrophil). As supportive treatments
were not uniform across the included studies, one may argue
that simultaneous use of other drugs (anti-viral drugs, and/or
interferon-α) as a part of supportive treatment might have
confounded (increased or decreased) the efficacy of the anti-
malarial drugs (15). This possibility, however, seems less likely,
as few studies have found no difference after excluding patients
receiving these drugs (15).
An interesting observation was that, studies fromUSA showed
a significantly increased risk of mortality compared to those from
outside USA. The same could be explained by the following
points in the USA study cohort: inclusion of a higher proportion
of patients with severe or critical illness, advanced age, and co-
morbidities. Among the included studies in the present review,
marked variation (high heterogeneity) was noted in the age group
(in the clinical trials majority were ≤50 yr of age, whereas, in
the observational studies majority were ≥60 yr of age), severity
of COVID-19 illness (around 72% of participants in the clinical
trials were having mild and moderate illness, whereas <40% of
the participants in the observational studies exhibited mild and
moderate illness), and inclusion of patients with co-morbidities
(diabetes, cardio-vascular disease, chronic lung disease, etc.)
among the study cohorts. We could not, however, carry out
sub-group analyses as per severity illness because of paucity of
data. Except for the severity of COVID-19 illness, the remaining
two characteristics (age group and inclusion of patients with
co-morbidities) of the study cohort could increase mortality
that is independent of the effect of CQ/HCQ (±Azithromycin).
This emphasizes the role of randomized double-blind trials in
establishing the actual efficacy (if any) of anti-malarial drugs,
as the chance of selection bias would be very low, and the
groups would be comparable. The dose schedule of CQ was
nearly uniform; however, the dose schedule of HCQ varied
widely among the studies (except for one large study, the
cumulative dose was equal or higher than the recommended
schedule in the remaining studies). There was, however, no
difference in the mortality rate. The median time from onset
of symptom to admission or treatment initiation was nearly
≤8 days in all but two studies, and, apart from one study,
others used CQ/HCQ within 48 h of admission/hospitalization
(not symptom onset). There was no significant difference in the
mortality rate between exposure/interventions and controls in
these sub-groups. This might be due to the fact that starting
anti-viral drugs (including HCQ/CQ) after 48 h of symptom
onset might not be beneficial as the golden window for antiviral
treatment (e.g., in influenza) is lost (48). This is difficult
in a hospitalized setting (may be possible in outpatient or
community setting); however, one RCT could able to use it
within 48 h of symptom onset (found a significantly shorter
time to clinical recovery and pneumonia resolution without any
mortality) (17).
Limitations
The studies were variable in many aspects (blinding of
participants and outcome assessors, patient selection,
severity of illness, dose schedule of the anti-malarial drugs,
timing of administration, measurement of inflammatory
markers and effect of the drugs on these markers, outcome
definition, and measurements). We could not determine
the effect of anti-malarial drugs in Covid-19 infection in
pediatric and adolescent population. As there were few
studies, results from all the secondary outcomes could not
be pooled.
Future Areas of Research
Future clinical trials should include good quality RCTs with
adequate sample size, should ideally be multi-centric, and should
focus on the variability noted in the present review. Pediatric and
adolescent population also need to be included in the ongoing
studies to guide recommendation in this group of patients. Both
CQ/HCQ should also be evaluated in non-hospitalized patients
with COVID-19 infection.
CONCLUSIONS
As very low quality evidence suggests an increased risk of
mortality and adverse event with HCQ plus Azithromycin
combination (not HCQ alone); caution should be exercised while
prescribing this combination for treatment of hospitalized adults
with COVID-19 infection. Multi-centric RCTs (including both
hospitalized and non-hospitalized patients) of a good quality are
required for any firm recommendation to be made during the
ongoing pandemic.
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